Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03564782 · ClinicalTrials.gov registry record · Early Phase 1
Examining Bioactivity of PVSRIPO in Invasive Breast Cancer
A Early Phase 1 study, sponsored by Istari Oncology.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT03564782 is a Early Phase 1 study that has completed, run by Istari Oncology. The registered enrollment target is 5 participants.
The verdict
NCT03564782, a Early Phase 1 study, has completed, sponsored by Istari Oncology.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a pilot study to examine PVSRIPO bioactivity in tumor tissue after intratumoral administration of PVSRIPO in women with invasive breast cancer.
Interventions
- BIOLOGICAL PVSRIPO
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-06-30 |
| Est. Completion | 2022-04-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03564782
The ClinicalTrials.gov registry entry for NCT03564782 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Istari Oncology, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PVSRIPO is the first listed.
NCT03564782 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03564782 about?
NCT03564782 is a clinical study titled "Examining Bioactivity of PVSRIPO in Invasive Breast Cancer". This is a pilot study to examine PVSRIPO bioactivity in tumor tissue after intratumoral administration of PVSRIPO in women with invasive breast cancer.
What is the current status of trial NCT03564782?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2019-06-30. Estimated completion is 2022-04-11.
What interventions are being tested in trial NCT03564782?
The interventions under investigation include: PVSRIPO (BIOLOGICAL).
Who is sponsoring clinical trial NCT03564782?
This trial is sponsored by Istari Oncology, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.